• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review.

作者信息

Izumi Hiroki, Yamasaki Akira, Ueda Yasuto, Sumikawa Takashi, Maeta Hiroyuki, Nakamoto Shu, Shimizu Eiji

机构信息

Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Japan; Department of Respiratory Medicine, Tottori Prefectural Central Hospital, Tottori, Japan.

Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Japan.

出版信息

Clin Lung Cancer. 2018 Jan;19(1):e63-e66. doi: 10.1016/j.cllc.2017.10.005. Epub 2017 Oct 19.

DOI:10.1016/j.cllc.2017.10.005
PMID:29126779
Abstract
摘要

相似文献

1
Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review.表皮生长因子受体（EGFR）突变型肺腺癌转化为鳞状细胞癌：1例报告及文献复习
Clin Lung Cancer. 2018 Jan;19(1):e63-e66. doi: 10.1016/j.cllc.2017.10.005. Epub 2017 Oct 19.
2
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.表皮生长因子受体酪氨酸激酶抑制剂耐药后 T790M 阳性肺腺癌的临床特征，重点是脑转移和生存。
Lung Cancer. 2018 Jul;121:12-17. doi: 10.1016/j.lungcan.2018.04.013. Epub 2018 Apr 17.
3
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.奥希替尼治疗原发性耐药导致小细胞肺癌转化：液体再活检T790M 检测问题。
Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.
4
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.表皮生长因子受体突变型肺腺癌患者接受酪氨酸激酶抑制剂治疗后出现表型改变为鳞状细胞癌的结局：一项荟萃分析及附加病例报告。
Lung Cancer. 2019 Jan;127:12-18. doi: 10.1016/j.lungcan.2018.11.016. Epub 2018 Nov 13.
5
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.获得性 EGFR L718V 突变介导非小细胞肺癌对奥希替尼的耐药性，但保留对阿法替尼的敏感性。
Lung Cancer. 2018 Apr;118:1-5. doi: 10.1016/j.lungcan.2018.01.015. Epub 2018 Jan 31.
6
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.表皮生长因子受体（EGFR）-突变型肺腺癌在奥希替尼治疗进展后出现EGFR G724S突变
Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.
7
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。
Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.
8
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.奥希替尼对比多西他赛联合贝伐珠单抗作为 EGFR T790M 突变型非小细胞肺癌三线治疗。
Lung Cancer. 2018 Jul;121:5-11. doi: 10.1016/j.lungcan.2018.04.012. Epub 2018 Apr 17.
9
Osimertinib for Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma.奥希替尼用于转化为T790M阳性鳞状细胞癌的表皮生长因子受体突变阳性肺腺癌
J Thorac Oncol. 2017 Oct;12(10):e167-e169. doi: 10.1016/j.jtho.2017.06.071.
10
Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.一名EGFR突变型肺腺癌患者在对奥希替尼产生获得性耐药后，肿瘤先转变为鳞状细胞癌，后又转变为肉瘤样癌：病例报告
Clin Lung Cancer. 2021 Jul;22(4):e536-e541. doi: 10.1016/j.cllc.2020.06.026. Epub 2020 Jul 5.

引用本文的文献

1
Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.揭示肺腺鳞癌转化中的免疫机制和治疗靶点。
Front Immunol. 2025 Jun 3;16:1542526. doi: 10.3389/fimmu.2025.1542526. eCollection 2025.
2
Response and Resistance to RAS Inhibition in Cancer.癌症中对RAS抑制的反应与抗性
Cancer Discov. 2025 Jul 3;15(7):1325-1349. doi: 10.1158/2159-8290.CD-25-0349.
3
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体（EGFR）突变型肺癌对奥希替尼耐药的策略
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
4
Evaluation of the ASPYRE-Lung targeted variant panel: a rapid, low-input solution for non-small cell lung cancer biomarker testing and experience from three independent sites.ASPYRE-Lung靶向变异检测板的评估：一种用于非小细胞肺癌生物标志物检测的快速、低投入解决方案及来自三个独立站点的经验
Transl Lung Cancer Res. 2024 Nov 30;13(11):3083-3095. doi: 10.21037/tlcr-24-525. Epub 2024 Nov 28.
5
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.肺腺癌中的组织学转化：机制与治疗时机的见解
J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.
6
Clonality Analysis for the Relationship between the Pulmonary Combined Neuroendocrine Carcinoma and "the So-Called Reported Histologic Transformation".肺复合性神经内分泌癌与“所谓的组织学转化”关系的克隆性分析
Cancers (Basel). 2023 Nov 29;15(23):5649. doi: 10.3390/cancers15235649.
7
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.奥希替尼治疗初治 EGFR T790M 阳性肺鳞癌的疗效：病例报告及文献复习。
Thorac Cancer. 2023 Oct;14(28):2886-2889. doi: 10.1111/1759-7714.15081. Epub 2023 Aug 28.
8
Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma.克隆动力学和空间转录组测序解析腺鳞癌的起源和表型可塑性。
NPJ Precis Oncol. 2023 Aug 26;7(1):80. doi: 10.1038/s41698-023-00430-8.
9
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.下一代测序技术阐明了为什么在 EGFR 突变型肺鳞癌的尸检病例中，一线奥希替尼治疗无效。
Thorac Cancer. 2023 Mar;14(7):709-713. doi: 10.1111/1759-7714.14807. Epub 2023 Jan 29.
10
Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.肺腺鳞癌肿瘤免疫微环境异质性及免疫治疗疗效的真实世界分析。
Front Immunol. 2022 Aug 12;13:944812. doi: 10.3389/fimmu.2022.944812. eCollection 2022.